Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Norgestimate/Ehinyl Estradiol; Folic acid · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| Norgestimate/Ehinyl Estradiol; Folic acid. | DRUG | - |
Inclusion Criteria: * Healthy, nonpregnant, nonlactating, nonsmoking women * Weighing at least 110 pounds with regular menstrual cycles * A body mass index between 16 and 29.9 kg/m2 * And having a hematocrit of at least 36% Exclusion Criteria: * History or presence of disorders commonly accepted ...
Norgestimate/ethinyl estradiol with folic acid is an investigational oral contraceptive combination that pairs the progestin norgestimate and the estrogen ethinyl estradiol with folic acid. It is being developed by Johnson & Johnson (ticker JNJ) and is in Phase 1 clinical development for contraception.
Norgestimate/ethinyl estradiol targets the progesterone receptor (PGR), where it acts as an agonist. Norgestimate is the progestin component and ethinyl estradiol is the estrogen component; together they act on hormonal pathways to suppress ovulation and support contraceptive effect. Folic acid is included as a supplemental vitamin rather than as a hormonal agent.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of norgestimate/ethinyl estradiol with folic acid. The product is an oral contraceptive tablet combining norgestimate, ethinyl estradiol, and folic acid, and it remains in clinical development.
Norgestimate/ethinyl estradiol with folic acid is in Phase 1 clinical development. It is an investigational product and is not approved; the only recorded trial is a completed Phase 1 study. No active trials are currently listed for this asset.
One trial is recorded for norgestimate/ethinyl estradiol with folic acid: NCT00709189, a completed Phase 1 bioequivalence study of the oral contraceptive tablet containing norgestimate and ethinyl estradiol with or without folic acid in healthy women. It enrolled 53 participants, was randomized, and was uncontrolled.